Literature DB >> 31806726

Opt-out screening for HIV, hepatitis B and hepatitis C: observational study of screening acceptance, yield and treatment outcomes.

Conor Grant1, Sarah O'Connell2, Darren Lillis3, Anne Moriarty2, Ian Fitzgerald4, Linda Dalby4, Ciaran Bannan2, Helen Tuite2, Brendan Crowley4, Patrick Plunkett3, Una Kennedy3, Geraldine McMahon3, Susan McKiernan5, Suzanne Norris5, Gerard Hughes6, Darragh Shields3, Colm Bergin2.   

Abstract

BACKGROUND: We initiated an emergency department (ED) opt-out screening programme for HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) at our hospital in Dublin, Ireland. The objective of this study was to determine screening acceptance, yield and the impact on follow-up care.
METHODS: From July 2015 through June 2018, ED patients who underwent phlebotomy and could consent to testing were tested for HIV, HBV and HCV using an opt-out approach. We examined acceptance of screening, linkage to care, treatment and viral suppression using screening programme data and electronic health records. The duration of follow-up ranged from 1 to 36 months.
RESULTS: Over the 36-month study period, there were 140 550 ED patient visits, of whom 88 854 (63.2%, 95% CI 63.0% to 63.5%) underwent phlebotomy and 54 817 (61.7%, 95% CI 61.4% to 62.0%) accepted screening for HIV, HBV and HCV, representing 41 535 individual patients. 2202 of these patients had a positive test result. Of these, 267 (12.1%, 95% CI 10.8% to 13.6%) were newly diagnosed with an infection and 1762 (80.0%, 95% CI 78.3% to 81.7%) had known diagnoses. There were 38 new HIV, 47 new HBV and 182 new HCV diagnoses. 81.5% (95% CI 74.9% to 87.0%) of known patients who were not linked were relinked to care after screening. Of the new diagnoses, 86.2% (95% CI 80.4 to 90.8%) were linked to care.
CONCLUSION: Although high proportions of patients had known diagnoses, our programme was able to identify many new infected patients and link them to care, as well as relink patients with known diagnoses who had been lost to follow-up. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  HIV; research, clinical; statistics; viral

Year:  2019        PMID: 31806726     DOI: 10.1136/emermed-2019-208637

Source DB:  PubMed          Journal:  Emerg Med J        ISSN: 1472-0205            Impact factor:   2.740


  4 in total

Review 1.  Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.

Authors:  Allison E Wang; Eric Hsieh; Barbara J Turner; Norah Terrault
Journal:  J Gen Intern Med       Date:  2022-04-28       Impact factor: 6.473

2.  Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations.

Authors:  Paul G Carty; Christopher G Fawsitt; Paddy Gillespie; Patricia Harrington; Michelle O'Neill; Susan M Smith; Conor Teljeur; Mairin Ryan
Journal:  Appl Health Econ Health Policy       Date:  2021-12-06       Impact factor: 3.686

3.  VirA+EmiC project: Evaluating real-world effectiveness and sustainability of integrated routine opportunistic hepatitis B and C testing in a large urban emergency department.

Authors:  Gaia Nebbia; Murad Ruf; Laura Hunter; Sooria Balasegaram; Terry Wong; Ranjababu Kulasegaram; Julian Surey; Zana Khan; Jack Williams; Basel Karo; Luke Snell; Barnaby Flower; Hannah Evans; Sam Douthwaite
Journal:  J Viral Hepat       Date:  2022-04-09       Impact factor: 3.517

4.  Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis.

Authors:  Tyler S Bartholomew; Hansel E Tookes; David P Serota; Czarina N Behrends; David W Forrest; Daniel J Feaster
Journal:  Int J Drug Policy       Date:  2020-07-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.